SCHEMBL1797157

SCHEMBL1797157

c1ccc2c(c1)CC[C@@H]2Nc1nccc2[nH]cnc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK1 P06493 2/20 0.48
AURKA O14965 1/20 0.44
RPS6KB1 P23443 1/20 0.44
PDPK1 O15530 1/20 0.43
EGFR P00533 1/20 0.43
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
GBA1 P04062 1/20 0.42
FADS1 O60427 1/20 0.41
NSD2 O96028 2/20 0.41
KDM4E B2RXH2 1/20 0.41
MEN1 O00255 1/20 0.41
ALDH1A1 P00352 1/20 0.41
TP53 P04637 1/20 0.41
CYP3A4 P08684 1/20 0.41
MAPT P10636 1/20 0.41
THRB P10828 1/20 0.41
TSHR P16473 1/20 0.41
MAPK1 P28482 1/20 0.41
CASP1 P29466 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22524329 0.81 AURKA (0.56) CDK1AURKARPS6KB1PDPK1EGFR
SCHEMBL22524331 0.81 AURKA (0.56) CDK1AURKARPS6KB1PDPK1EGFR
SCHEMBL6746639 0.77 PDPK1 (0.43) CDK1AURKARPS6KB1PDPK1EGFR
SCHEMBL1798451 0.75 FADS1 (0.45) CDK1AURKARPS6KB1PDPK1EGFR
SCHEMBL1795052 0.75 AURKA (0.46) AURKARPS6KB1PDPK1EGFRCA1
SCHEMBL19010820 0.73 CDK1 (0.47) CDK1AURKARPS6KB1PDPK1EGFR
SCHEMBL8544073 0.73 GBA1 (0.50) AURKARPS6KB1PDPK1EGFRCA1
SCHEMBL20568592 0.72 EGFR (0.57) AURKARPS6KB1PDPK1EGFRGBA1
SCHEMBL2476603 0.71 CYP3A4 (0.46) CDK1AURKARPS6KB1PDPK1EGFR
SCHEMBL782972 0.69 EGFR (0.51) CDK1AURKARPS6KB1PDPK1EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210070798-A1 Inhibitors of E1 activating enzymes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2021-03-11 US disclosed
US-20180086785-A1 SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES MILLENNIUM PHARMACEUTICALS, INC. 2018-03-29 US disclosed
US-20170073367-A9 SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES MILLENIUM PHARMACEUTICALS, INC. 2017-03-16 US disclosed
US-20160194348-A1 SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES MILLENNIUM PHARM INC (US) 2016-07-07 US disclosed
US-20140256668-A9 SUBSTITUTED PYRROLO]2,3-D]PYRIMIDINES MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-09-11 US disclosed
US-20130338094-A1 SUBSTITUTED PYRROLO]2,3-D]PYRIMIDINES MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-12-19 US disclosed
EP-1848718-B1 INHIBITORS OF E1 ACTIVATING ENZYMES MILLENNIUM PHARM INC (US) 2012-08-01 EP disclosed
US-20110136834-A1 INHIBITORS OF E1 ACTIVATING ENZYMES MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-06-09 US disclosed
US-7951810-B2 Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of E1 activating enzymes MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-05-31 US disclosed
US-20060189636-A1 Inhibitors of E1 activating enzymes MILLENNIUM PHARMACEUTICALS, INC. (US) 2006-08-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180086785-A1 SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES TYMP, TYMS, PPA1 CDK1 14/4885AURKA 1525/4885RPS6KB1 330/4885
US-20170073367-A9 SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES TYMP, TYMS, PPA1 CDK1 14/4885AURKA 1525/4885RPS6KB1 330/4885
US-20110136834-A1 INHIBITORS OF E1 ACTIVATING ENZYMES ECE1, RNASE1, RCE1 CDK1 4/4885AURKA 1673/4885RPS6KB1 440/4885
US-20140256668-A9 SUBSTITUTED PYRROLO]2,3-D]PYRIMIDINES DPYD, CCND3, POLD3 CDK1 81/4885AURKA 1161/4885RPS6KB1 235/4885
US-20160194348-A1 SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES TYMP, TYMS, PPA1 CDK1 14/4885AURKA 1525/4885RPS6KB1 330/4885
US-20210070798-A1 Inhibitors of E1 activating enzymes ECE1, RNASE1, RCE1 CDK1 4/4885AURKA 1673/4885RPS6KB1 440/4885
US-20130338094-A1 SUBSTITUTED PYRROLO]2,3-D]PYRIMIDINES DPYD, CCND3, POLD3 CDK1 81/4885AURKA 1161/4885RPS6KB1 235/4885
US-20060189636-A1 Inhibitors of E1 activating enzymes ECE1, RNASE1, RCE1 CDK1 4/4885AURKA 1673/4885RPS6KB1 440/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.